ANCA-associated vasculitis: New options beyond steroids and cytotoxic drugs

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 689-703

  Selamet, Umet ^a   Kovaliv, Yuriy B ^b   Savage, Caroline O ^a   Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

ANCA; Gene therapy; Immunosuppression; Microscopic polyangiitis; Pathogenesis vasculitis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; FARNESYLTHIOSALICYLIC ACID; HEXAPEPTIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 18 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RUBOXISTAURIN; STEROID; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ADJUVANT THERAPY; ALOPECIA; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; B LYMPHOCYTE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER RISK; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CROSS REACTION; CYTOKINE PRODUCTION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE THERAPY; GLOMERULONEPHRITIS; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMETHOD COMPARISON; KIDNEY FAILURE; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PASSIVE IMMUNIZATION; PLASMAPHERESIS; PNEUMONIA; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; CYTOTOXINS; DRUG MONITORING; GENE THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY DISEASES; KIDNEY FAILURE; STEROIDS; T-LYMPHOCYTES; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 34248362846     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.689     Document Type: Review

References (120)

1. JENNETTE JC, WILKMAN AS, FALK RJ: Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol. (1989) 135:921-930.
2. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides: the proposal of an International Consensus Conference. Arthritis Rheum. (1994) 37:187-192.
3. WATTS RA, LANE S, SCOTT DG: What is known about the epidemiology of the vasculitides? Best Pract. Res. Clin. Rheumatol. (2005) 19(2):191-207.
4. HARPER L, SAVAGE CO: ANCA-associated renal vasculitis at the end of the twentieth century - a disease of older patients. Rheumatology (Oxf.) (2005) 44(4):495-501.
5. BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. (2003) 41(4):776-784.
6. FALK RJ, HOGAN S, CAREY TS, JENNETTE JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann. Int. Med. (1990) 113:656-663.
7. HOGAN S, NACHMAN P, WILKMAN A, JENNETTE J, FALK R: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-assocaited microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. (1996) 7(1):23-32.
8. HAUER HA, BAJEMA IM, VAN HOUWELINGEN HC et al.: Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. (2002) 62(5):1732-1742.
9. BANSAL PJ, TOBIN MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. (2004) 93(4):398-401.
10. CHOI HK, SLOT MC, PAN G, WEISSBACH CA, NILES JL, MERKEL PA: Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum. (2000) 43(11):2488-2492.
11. COHEN TERVAERT J, POPA E, BOS N: The role of superantigens in vasculitis. Curr. Opin. Rheum. (1999) 11:24-33.
12. LANE SE, WATTS RA, BENTHAM G, INNES NJ, SCOTT DG: Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. (2003) 48(3):814-823.
13. HAGEN E, DAHA M, HERMANS J et al.: Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. (1998) 53:743-753.
14. BOOMSMA MM, STEGEMAN CA, VAN DER LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. (2000) 43(9):2025-2033.
15. XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. (2002) 110(7):955-963.
16. LITTLE MA, SMYTH CL, YADAV R et al.: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood (2005) 106(6):2050-2058.
17. PFISTER H, OLLERT M, FROHLICH LF et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 104(5):1411-1418.
18. TRAVIS WD, HOFFMAN GS, LEAVITT RY, PASS HI, FAUCI AS: Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am. J. Surg. Pathol. (1991) 15(4):315-333.
19. COCKWELL P, BROOKS C, ADU D, SAVAGE C: Interleukin-8: a pathogenetic role in antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis. Kidney Int. (1999) 55:852-863.
20. XIAO H, HEERINGA P, LIU Z et al.: The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. (2005) 167(1):39-45.
21. HARPER L, COCKWELL P, ADU D, SAVAGE C: Neutrophil priming and apoptosis in ANCA-associated vasculitis. Kidney Int. (2001) 59:1729-1738.
22. MULLER KUBOLD A, MESANDER G, STEGEMAN C, KALLENBERG C, COHEN TERVAERT J: Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? Clin. Exp. Immunol. (1998) 114:491-499.
23. FALK RJ, TERRELL RS, CHARLES LA, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. USA (1990) 87:4115-4119.
24. ZHOU Z, RICHARD C, MENARD HA: De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells. J. Rheumatol. (2000) 27(10):2406-2411.
25. CONDLIFFE AM, CHILVERS ER, HASLETT C, DRANSFIELD I: Priming differentially regulates neutrophil adhesion molecule expression/ function. Immunology (1996) 89:105-111.
26. MCLEISH KR, KLEIN JB, LEDERER ED, HEAD KZ, WARD RA: Azotemia, TNF-α, and LPS prime the human neutrophil oxidative burst by distinct mechanisms. Kidney Int. (1996) 50:407-416.
27. DEWAS C, DANG PM, GOUGEROT-POCIDALO MA, EL-BENNA J: TNF-α induces phosphorylation of p47 (phox) in human neutrophils: partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-α and granulocyte-macrophage colony-stimulating factor. J. Immunol. (2003) 171(8):4392-4398.
28. KETTRITZ R, SCHREIBER A, LUFT FC, HALLER H: Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. (2001) 12(1):37-46.
29. YUO A, KITAGAWA S, KASAHARA T, MATSUSHIMA K, SAITO M, TAKAKU F: Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood (1991) 78(10):2708-2714.
30. HUUGEN D, XIAO H, VAN ESCH A et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am. J. Pathol. (2005) 167(1):47-58.
31. LITTLE MA, BHANGAL G, SMYTH CL et al.: Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2006) 17(1):160-169.
32. HEWINS P, MORGAN M, WILLIAMS JM, SAVAGE CO, HARPER L: IL-18 is up-regulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int. (2006) 69:605-615.
33. i heterotrimeric G protein by ANCA IgG F(ab′)2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. (2003) 14(3):661-669.
34. HEWINS P, WILLIAMS JM, WAKELAM MJ, SAVAGE CO: Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18. J. Am. Soc. Nephrol. (2004) 15(3):796-808.
35. RADFORD D, LORD J, SAVAGE C: The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clin. Exp. Immunol. (1999) 118:171-179.
36. BEN-SMITH A, DOVE S, MARTIN A, WAKELAM M, SAVAGE C: Anti-neutrophil cytoplasmic autoantibodies from patients with systemic vasculitis activate neutrophils via distinct signalling cascades compared to conventional Fcγ receptor ligation. Blood (2001) 981:1448-1455.
37. WILLIAMS JM, SAVAGE CO: Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. (2005) 16(1):90-96.
38. 2 integrins in neutrophil activation by anti-proteinase-3 or anti-myeloperoxidase antibodies. Clin. Exp. Immunol. (2003) 134(2):344-350.
39. SAVAGE CO, HARPER L, HOLLAND M: New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. (2002) 14(1):15-22.
40. 2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol. (2004) 30:30.
41. HARPER L, REN Y, SAVILL J, ADU D, SAVAGE C: Dysregulated neutrophil apoptosis in systemic vasculitis. Am. J. Pathol. (2000) 157:211-220.
42. DAY CJ, HEWINS P, SAVAGE CO: New developments in the pathogenesis of ANCA-associated vasculitis. Clin. Exp. Rheumatol. (2003) 21(6 Suppl. 32):S35-S48.
43. LAMPRECHT P, OFF BALANCE: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin. Exp. Immunol. (2005) 141(2):201-210.
44. GISCOMBE R, WANG XB, KAKOULIDOU M, LEFVERT AK: Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Int. Med. (2006) 260(3):224-230.
45. MARINAKI S, NEUMANN I, KALSCH AI et al.: Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. (2005) 140(1):181-191.
46. POPA ER, STEGEMAN CA, BOS NA, KALLENBERG CG, TERVAERT JW: Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. (1999) 103(5 Part 1):885-894.
47. PENDERGRAFT WF III, PRESTON GA, SHAH RR et al.: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat. Med. (2004) 10(1):72-79.
48. FAUCI AS, HAYNES BF, KATZ P WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Int. Med. (1983) 98:76-85.
49. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener's granulomatosis: an analysis of 158 patients. Ann. Int. Med. (1992) 116:488-498.
50. DE GROOT K, ADU D, SAVAGE C: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. (2001) 16:2018-2027.
51. PUSEY CD, REES AJ, EVANS DJ, PETERS DK, LOCKWOOD CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. (1991) 40(4):757-763.
52. JAYNE DRW, GASKIN G, RASMUSSEN N et al.: Randomised trial of plasma exchange versus methyl prednisolone for severe renal vasculitis. N. Engl. J. Med. (2006) (In Press).
53. KLEMMER PJ, CHALERMSKULRAT W, REIF MS, HOGAN SL, HENKE DC, FALK RJ: Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney Dis. (2003) 42(6):1149-1153.
54. THOMAS-GOLBANOV C, SRIDHARAN S: Novel therapies in vasculitis. Expert Opin. Investig. Drugs (2001) 10(7):1279-1289.
55. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. (2005) 52(8):2461-2469.
56. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. (2003) 349(1):36-44.
57. SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. (2004) 51(2):269-273.
58. ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 47(2-3):85-118.
59. DOOLEY MA: Mycophenylate mofetil: what role in the treatment of lupus? Lupus (2006) 15(3):179-182.
60. LAU CH, COMER M, LIGHTMAN S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Exp. Ophthalmol. (2003) 31(6):487-491.
61. NOWACK R, GOBEL U, KLOOKER P, HERGESALL O, ANDRASSY K, VAN DER WOUDE F: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study of 11 patients with renal involvement. J. Am. Soc. Nephrol. (1999) 10:1965-1971.
62. LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. (2004) 51(2):278-283.
63. STEGEMAN CA, COHEN-TERVAERT JW: Mycophenolate mofetil for remission induction in patients with active Wegener's granulomatosis intolerant of cyclophosphamide. J. Am. Soc. Nephrol. (2000) 11:98A.
64. JOY MS, HOGAN SL, JENNETTE JC, FALK RJ, NACHMAN PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. (2005) 20(12):2725-2732.
65. PONTICELLI C, TARANTINO A: Promising new agents in the prevention of transplant rejection. Drugs RD (1999) 1(1):55-60.
66. BIRCK R, WARNATZ K, LORENZ H et al.: 15-Deoxyspergualin for refractory Wegenr's granulomatosis and microscopic polyangiitis: results of a multicentre trial. J. Am. Soc. Nephrol. (2001) 12:191A.
67. SCHMITT WH, BIRCK R, HEINZEL PA et al.: Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant. (2005) 20(6):1083-1092.
68. METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxf.) (2004) 43(3):315-320.
69. NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. (1993) 43:682-692.
70. TESAR V, MASEK Z, RYCHLIK I et al.: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol. Dial. Transplant. (1998) 13(7):1662-1667.
71. KINDLER V, SAPPINO AP, GRAU GE, PIGUET PF, VASSALLI P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 56(5):731-740.
72. BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2004) 15(3):717-721.
73. STONE J, UHLFELDER M, HELLMANN D, CROOK S, BEDOCS N, HOFFMAN G: Etanercept combined with conventional treatment in Wegener's granulomatosis. Arthritis Rheum. (2001) 44:1149-1154.
74. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. (2005) 352(4):351-361.
75. STONE JH, HOLBROOK JT, MARRIOTT MA et al.: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. (2006) 54(5):1608-1618.
76. SANDBORN WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. (2003) 5(6):501-505.
77. SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. (2002) 301(2):418-426.
78. VOSWINKEL J, MUELLER A, KRAEMER JA et al.: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. (2006) 65(7):859-864.
79. KRUMBHOLZ M, SPECKS U, WICK M, KALLED SL, JENNE D, MEINL E: BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. (2005) 25(4):298-302.
80. CHAMBERS SA, ISENBERG D: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus (2005) 14(3):210-214.
81. KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2005) 173(2):180-187.
82. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. (2006) 65(7):853-858.
83. TIPPING PG, HOLDSWORTH SR: T cells in crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2006) 17(5):1253-1263.
84. SZPIRIT W, RASMUSSEN N, PEDERSON J: Plasma exchange and cyclosporin A in Wegener's granulomatosis: a controlled study. Int. J. Artif. Organs (1996) 10:51-54.
85. HAUBITZ M, KOCH KM, BRUNKHORST R: Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol. Dial. Transplant. (1998) 13(8):2074-2076.
86. SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, VAN DER WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. (2004) 65(4):1440-1448.
87. LOCKWOOD C, THIRU S, STEWART S et al.: Treatment of refractory Wegener's granulomatosis with humanised. monoclonal antibodies. QJ Med. (1996) 89:903-912.
88. SANSOM DM, WALKER LS: The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. (2006) 212:131-148.
89. LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1(9):793-801.
90. GREENE JL, LEYTZE GM, EMSWILER J et al.: Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. (1996) 271(43):26762-26771.
91. KREMER JM, DOUGADOS M, EMERY P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(8):2263-2271.
92. ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. (1999) 103(9):1243-1252.
93. VINCENTI F, LARSEN C, DURRBACH A et al.: Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. (2005) 353(8):770-781.
94. REYNOLDS J, TAM FW, CHANDRAKER A et al.: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. (2000) 105(5):643-651.
95. GROHMANN U, ORABONA C, FALLARINO F et al.: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. (2002) 3(11):1097-1101.
96. UEDA H, HOWSON JM, ESPOSITO L et al.: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 423:506-511.
97. ZHOU Y, HUANG D, PARIS PL, SAUTER CS, PROCK KA, HOFFMAN GS: An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. (2004) 50(8):2645-2650.
98. STEEBER DA, VENTURI GM, TEDDER TF: A new twist to the leukocyte adhesion cascade: intimate cooperation is key. Trends Immunol. (2005) 26(1):9-12.
99. SALMELA K, WRAMNER L, EKBERG H et al.: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation (1999) 67(5):729-736.
100. KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37(7):992-999.
101. PALL AA, HOWIE AJ, ADU D et al.: Glomerular vascular cell adhesion molecule-1 expression in renal vasculitis. J. Clin. Pathol. (1996) 49:238-242.
102. VUORTE J, LINDSBERG PJ, KASTE M et al.: Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J. Immunol. (1999) 162(4):2353-2357.
103. FORBESS JM, HIRAMATSU T, NOMURA F et al.: Anti-CD11b monoclonal antibody improves myocardial function after six hours of hypothermic storage. Ann. Thorac. Surg. (1995) 60(5):1238-1244.
104. ANDERSON ME, SIAHAAN TJ: Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides (2003) 24(3):487-501.
105. YUSUF-MAKAGIANSAR H, ANDERSON ME, YAKOVLEVA TV, MURRAY JS, SIAHAAN TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. (2002) 22(2):146-167.
106. ARNAUD C, BRAUNERSREUTHER V, MACH F: Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc. Med. (2005) 15(6):202-206.
107. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7(6):687-692.
108. CHOI M, ROLLE S, RANE M, HALLER H, LUFT FC, KETTRITZ R: Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. (2003) 63(1):96-106.
109. AIELLO LP, CLERMONT A, ARORA V, DAVIS MD, SHEETZ MJ, BURSELL SE: Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. (2006) 47(1):86-92.
110. NONAKA A, KIRYU J, TSUJIKAWA A et al.: PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. (2000) 41(9):2702-2706.
111. KARUSSIS D, ABRAMSKY O, GRIGORIADIS N et al.: The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. (2001) 120(1-2):1-9.
112. CLARKE HC, KOCHER HM, KHWAJA A, KLOOG Y, COOK HT, HENDRY BM: Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J. Am. Soc. Nephrol. (2003) 14(4):848-854.
113. EVANS CH, GOUZE E, GOUZE JN, ROBBINS PD, GHIVIZZANI SC: Gene therapeutic approaches - transfer in vivo. Adv. Drug Deliv. Rev. (2006) 58(2):243-258.
114. IMAI E, TAKABATAKE Y, MIZUI M, ISAKA Y: Gene therapy in renal diseases. Kidney Int. (2004) 65(5):1551-1555.
115. YOKOO T, OHASHI T, UTSUNOMIYA Y et al.: Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood (2001) 98(1):57-64.
116. TOMITA N, MORISHITA R, LAN HY et al.: In vivo administration of a nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2000) 11(7):1244-1252.
117. CAO CC, DING XQ, OU ZL et al.: In vivo transfection of NF-κB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int. (2004) 65(3):834-845.
118. LITTLE MH: Regrow or repair: potential regenerative therapies for the kidney. J. Am. Soc. Nephrol. (2006) 17(9):2390-2401.
119. MARINAKI AM, ANSARI A, DULEY JA et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics (2004) 14(3):181-187.
120. TAKADA K, AREFAYENE M, DESTA Z et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. (2004) 50(7):2202-2210.